Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Total Liabilities (2016 - 2025)

Purple Biotech has reported Total Liabilities over the past 7 years, most recently at $7.5 million for Q4 2022.

  • Quarterly Total Liabilities rose 47.76% to $7.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $7.5 million through Dec 2022, up 47.76% year-over-year, with the annual reading at $7.5 million for FY2022, 47.76% up from the prior year.
  • Total Liabilities was $7.5 million for Q4 2022 at Purple Biotech, up from $6.7 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $30.0 million in Q2 2020 and troughed at $3.7 million in Q4 2018.
  • The 5-year median for Total Liabilities is $6.3 million (2019), against an average of $7.6 million.
  • Year-over-year, Total Liabilities skyrocketed 384.27% in 2020 and then crashed 84.38% in 2021.
  • A 5-year view of Total Liabilities shows it stood at $3.7 million in 2018, then increased by 3.76% to $3.9 million in 2019, then rose by 4.98% to $4.1 million in 2020, then grew by 25.7% to $5.1 million in 2021, then soared by 47.76% to $7.5 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Total Liabilities are $7.5 million (Q4 2022), $6.7 million (Q3 2022), and $6.3 million (Q2 2022).